B+
Bull case
25%
Probability
Target price
$4.20
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
XFOR
X4FNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
FDA alignment on the smaller 4WARD trial may improve the odds of timely enrollment. X4 reported $208 million of cash and marketable securities at June 30, 2026 and said its runway extends into 2029; U.S.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -40.1.
What can break
4WARD enrollment could slip beyond year-end 2026 despite the smaller target. [#PR-2026-09-08]
Momentum
12
Value
41
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.10 · Bull $4.20 · Bear $1.50Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $11.60
Why
Momentum12 · Δ7d +3.6
Value41 · Δ7d -0.1
Sentiment47 · Δ7d -40.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -40.1.
Contradictions & invalidation
- • 4WARD enrollment could slip beyond year-end 2026 despite the smaller target. [#PR-2026-09-08]
- • European partner milestones are contingent on future regulatory and commercial achievements, not assured revenue. [#PR-EARNINGS-2026-08-06]
- • The revised sample size does not establish efficacy, FDA feedback is nonbinding, and enrollment has yet to finish.
Catalyst clock
2026-09-08
FDA alignment on revised 4WARD trial size
Lead driver: Sentiment · See AI snapshot
Momentum
12
8% active weight
Current posture
7d trendFlat
Δ7d
+3.6
Δ21d
+3.6
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
47
45% active weight
Current posture
7d trendSoftening
Δ7d
-40.1
Δ21d
-40.1
Why this grade
Composite grade F. Momentum 11.6 / Value 40.6 / Sentiment 46.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$3.10
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$321.24M
Beta
0.46
Shares Out
99.15M
P/E (TTM) · Derived
-1.7
P/S (TTM)
9.88
P/FCF (TTM) · Derived
-0.49
Rev YoY
+346.3%
EPS YoY
-96.3%
Gross Margin
+80.8%
Op Margin
-554.7%
Net Debt
-$176.52M
Current Ratio
11.30
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data